What is the price of Jaguar Health (JAGX) today?

The price of Jaguar Health (JAGX) today is $ 0.40, with return of -90.85% compared to the last year. The price of Jaguar Health (JAGX) started the year trading around $ 0.93 and today it is at $ 0.40. Follow the real-time price chart, the historical price of Jaguar Health (JAGX) and international markets.

When does Jaguar Health (JAGX) pay dividends?

Jaguar Health (JAGX) did not distribute dividends in the last year.

Is Jaguar Health (JAGX) worth it?

Currently, Jaguar Health (JAGX) is priced at $ 0.40, with a P/E of -0.02%, representing a deviation of -11,162% from its historical average P/E. In the last year, the stock showed a variation of -90.85 in its price and distributed $ 0.00 in dividends, resulting in a Dividend Yield of 0.00%. The total shareholder return was -90.85%.It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

How can I buy Jaguar Health (JAGX) stock?

Investing in stocks of Jaguar Health (JAGX) can be done in two ways: by buying the stock abroad. The stock is the original stock, traded on international exchanges. By buying it, you invest with money outside Brazil, which brings greater geographical and currency diversification.BDR is a receipt for that stock, traded on the B3 with reais, through a brazilian brokerage. Although the money remains in Brazil, the BDR still offers diversification, as it represents a foreign company and is linked to the dollar.

How much would 100 shares of Jaguar Health (JAGX) yield today?

The yield of Jaguar Health (JAGX) was -33.58% in the last month, -90.85% in the last year and -100.00% in the last 5 years (already considering appreciation and dividends).In the last 12 months, the company paid a total of $ 0.00 in dividends, with a Dividend Yield of 0.00%.If you wanted to buy 100 stocks of Jaguar Health (JAGX) today, the total investment would be $ 40.00, based on the current price of $ 0.40.If past performance were to repeat, the return on your investment would be:In 1 year: $ 3.66In 5 years: $ 0.00In 10 years: $ 0.00It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

Jaguar Health (JAGX): Stock Price, Earnings & Key Metrics

	p/e	p/bv	ROE	dy	market cap	net margin
JNJ	21.84	7.39	33.81%	2.14%	$ 585.48 B	28.46%
PFE	20.72	1.73	8.35%	6.07%	$ 161.03 B	12.42%
ABBV	87.32	0.00	0.00%	3.18%	$ 369.02 B	6.91%
NVO	10.48	5.40	51.50%	4.56%	$ 164.23 B	33.05%
MRK	16.43	0.00	0.00%	2.71%	$ 300.00 B	28.08%
AZN	30.87	6.48	20.99%	1.57%	$ 315.61 B	17.41%
GILD	20.39	7.67	37.62%	2.28%	$ 173.52 B	28.90%
BMY	17.20	-3.56	-20.72%	4.18%	$ 121.35 B	14.64%
ZTS	19.33	15.51	80.25%	1.72%	$ 51.66 B	28.23%
REGN	17.42	2.51	14.41%	0.47%	$ 78.47 B	31.41%
HALO	24.01	155.91	649.21%	0.00%	$ 7.61 B	22.69%
AMGN	24.32	21.66	89.06%	2.78%	$ 187.54 B	20.98%
MCK	25.06	-1,098.65	-4,383.84%	0.36%	$ 108.77 B	1.09%
VRTX	28.19	5.97	21.18%	0.00%	$ 111.43 B	32.94%
CAH	30.39	-18.71	-61.56%	0.95%	$ 50.52 B	0.68%
ADMA	14.89	4.58	30.78%	0.00%	$ 2.19 B	28.80%
BIIB	20.16	1.43	7.08%	0.00%	$ 26.07 B	13.07%
HRMY	9.96	1.82	18.24%	0.00%	$ 1.58 B	18.27%

Jaguar Health, Inc. is a U.S.-based biotechnology company focused on developing plant-based medicines for gastrointestinal disorders in humans and animals. The company specializes in therapies derived from botanical sources, targeting conditions related to intestinal health.

Its business model centers on the development, regulatory approval, and commercialization of treatments for chronic and infectious gastrointestinal diseases.

Core activities include:

Development of plant-based gastrointestinal therapies
Clinical research for chronic and infectious enteric diseases
Commercialization of approved treatments
Expansion of therapeutic applications and formulations
Partnerships for international distribution and regulatory access

The company’s portfolio includes treatments targeting diarrhea associated with various medical conditions, as well as therapies for chronic gastrointestinal disorders and neglected tropical diseases.

Jaguar Health operates primarily in the United States, with expansion efforts in Latin America, Africa, and other emerging markets, often through partnerships and regulatory initiatives.

Its performance is influenced by clinical trial outcomes, regulatory approvals, funding availability, competition in the biotechnology sector, and demand for gastrointestinal treatments.

Jaguar Health, Inc. is listed on the Nasdaq under the ticker JAGX.

History and Development

Jaguar Health traces its origins to 2013, with the founding of Jaguar Animal Health, focused on developing plant-derived therapies for gastrointestinal conditions.

A key milestone occurred in 2017, when Jaguar Animal Health merged with Napo Pharmaceuticals, combining botanical research capabilities with clinical development and commercialization expertise.

Following the merger, the company focused on advancing its lead products, securing regulatory approvals, and expanding clinical research into additional indications.

Over time, Jaguar Health broadened its international strategy, pursuing regulatory approvals and partnerships in regions affected by gastrointestinal diseases, including emerging markets.

Today, the company continues to develop plant-based therapeutics, focusing on specialized gastrointestinal conditions and expanding its presence in global healthcare markets.

JAGX

Jaguar Health Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment JAGX

review the fundamentals of Jaguar Health shares

P/E

P/S (PSR)

P/BV

DIVIDEND YIELD (DY)

ROA

ROE

ROIC

NET MARGIN

GROSS MARGIN

OPERATING MARGIN

EV/EBITDA

EV/EBIT

PRICE-TO-ASSETS

BVPS

EPS

EQUITY-TO-ASSETS RATIO

LIABILITIES / ASSETS

CAGR REVENUE 5 YEARS

CAGR PROFIT 5 YEARS

If you had invested (change) 2 years years ago, ago, you would now have

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Jaguar Health

Jaguar Health Inc.

United States

13 years

2015

34

History and Development

Additional Information

PROFIT X PRICE JAGX

Financial Results JAGX

JAGX cash flow

Asset, Revenue and Profit Growth - JAGX

JAGX balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

PFE - Pfizer

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca